Nykode Therapeutics ASA (NYKD)
Oslo Stock Exchange · Norway · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 3.150 |
|---|---|
| 52-week range | 2.058 – 5.200 |
| Return, 1 month / 3 months | −19.9% / +2.4% |
| Return, 1 year / 3 years | +31.8% / −75.4% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 79.3% |
| Worst drawdown (1 year) | -37.4% |
| Average daily value traded | 9.16M NOK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nykode Therapeutics ASA is a clinical-stage biotech company based in Norway that designs vaccines and immunotherapies. Its modular technology platform delivers antigens to the immune system to trigger targeted responses, and the company applies it to therapeutic cancer vaccines and preventive vaccines against infectious diseases. It works with partners and collaborators on development programmes, and its pipeline spans candidates for various cancers and infections.
Nykode Therapeutics ASA trades under the code NYKD on the Oslo Stock Exchange in Norway, with its price quoted in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nykode Therapeutics ASA (NYKD) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 3.150 on 23 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 157 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 31.8% and over the last three months it rose 2.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -4.7% | ||
| From 52-week high | -36.9% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.4% | ||
| 6-month return | -1.1% | ||
| 12-month return, skipping the last month | 64.6% | ||
| Stability (higher is calmer) | 25 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 79.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.4% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 9.16M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | −19.9% |
| 3 months | +2.4% |
| 6 months | −1.1% |
| 1 year | +31.8% |
| 3 years | −75.4% |
| 5 years | −92.6% |
Signals
| 50-day / 200-day average | 3.814 / 3.306 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.166 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 May 2025 | NOK 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.